<DOC>
	<DOC>NCT01074086</DOC>
	<brief_summary>A phase I clinical study in evaluation of RAD 001 with aracytine and daunorubicine in AML treatment of patients older less than 65 years in relapse</brief_summary>
	<brief_title>Phase I Study in RAD 001 Patients With Relapse AML</brief_title>
	<detailed_description>The primary objective of the study is to determinate the maximal tolerate dose and evaluate the toxicity of RAD 001 in patients older less than 65 years in AML relapse in association with a conventional chemotherapy 5Aracytine and Daunorubicine) in an dose escalated phase I study.</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>patients from 18 to 65 years old AML in relapse more than 1 year after CR inform consent signed age more than 65 cardiac insufficiency renal insufficiency hepatic disease other type of AML blastic MCL HIV positive serology other malignancy pulmonary infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>RAD 001 in relapsed AML</keyword>
</DOC>